Literature DB >> 25332569

A Case of Advanced Primary Thyroid Double-Hit B Cell Lymphoma in Which Complete Remission has been Maintained After High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Performed During the Second Remission, with a Review of the Literature.

Yasunobu Sekiguchi1, Asami Shimada2, Hidenori Imai1, Mutsumi Wakabayashi1, Keiji Sugimoto1, Noriko Nakamura3, Tomohiro Sawada3, Yasunori Ohta4, Norio Komatsu5, Masaaki Noguchi1.   

Abstract

A 50-year-old woman who presented with a mass in the thyroid gland was diagnosed as having diffuse large B-cell lymphoma (DLBCL) by biopsy in August 2011. The tumor had a complex chromosomal karyotype, including 8q24 (C-MYC) and 18q21(BCL-2), and fluorescence in situ hybridization confirmed split signals of C-MYC and BCL-2. BCL-2/IgH and C-MYC/IgH fusion signals were also observed. Three courses of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) therapy were given, followed by thyroid gland irradiation. She was achieved complete remission (CR). In January 2012, a mass appeared in the right breast, which was diagnosed as relapse by biopsy. CR was achieved again after the 4th course of R-CHOP therapy, and one course of rituximab, etoposide, methylprednisolone, cytarabine, cisplatin (R-ESHAP) therapy was given. Thereafter, CR has been maintained after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. There have been only 3 reported cases of primary thyroid C-MYC and BCL-2 double-hit lymphoma, including the present case; 2 of the cases were cases of DLBCL. R-CHOP therapy, irradiation and autologous peripheral blood stem cell transplantation are expected to be effective for such patients.

Entities:  

Keywords:  BCL-2; C-MYC; Diffuse large B-cell lymphoma; Double hit lymphoma; Thyroid

Year:  2014        PMID: 25332569      PMCID: PMC4192151          DOI: 10.1007/s12288-013-0312-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  24 in total

1.  Abstracts from the 77th Annual Meeting of the American Thyroid Association, Phoenix, Arizona, USA, October 11-15, 2006.

Authors: 
Journal:  Thyroid       Date:  2006-09       Impact factor: 6.568

2.  Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center.

Authors:  Rakesh Katna; Tanuja Shet; Manju Sengar; Hari Menon; Siddharth Laskar; Kumar Prabhash; Anil D'Cruz; Reena Nair
Journal:  Head Neck       Date:  2012-02-24       Impact factor: 3.147

3.  Localized non-Hodgkin lymphoma involving the thyroid gland.

Authors:  C S Ha; K M Shadle; L J Medeiros; R B Wilder; M A Hess; F Cabanillas; J D Cox
Journal:  Cancer       Date:  2001-02-15       Impact factor: 6.860

4.  Occurrence and prognosis of extranodal lymphomas.

Authors:  C Freeman; J W Berg; S J Cutler
Journal:  Cancer       Date:  1972-01       Impact factor: 6.860

5.  Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study.

Authors:  C Onal; Y X Li; R C Miller; P Poortmans; N Constantinou; D C Weber; B M Atasoy; S Igdem; M Ozsahin; E Ozyar
Journal:  Ann Oncol       Date:  2010-06-29       Impact factor: 32.976

6.  Double-hit lymphoma at second relapse of Burkitt-like lymphoma: a case report.

Authors:  Hiroaki Tanaka; Shinichiro Hashimoto; Daijiro Abe; Shio Sakai; Toshiyuki Takagi
Journal:  J Clin Exp Hematop       Date:  2011

7.  Characteristics and prognosis of primary thyroid non-Hodgkin's lymphoma in Chinese patients.

Authors:  Tuan-Qi Sun; Xiao-Li Zhu; Zhuo-Ying Wang; Chao-Fu Wang; Xiao-Yan Zhou; Qing-Hai Ji; Yi Wu
Journal:  J Surg Oncol       Date:  2010-06-01       Impact factor: 3.454

8.  High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study.

Authors:  Michael Mian; Gianluca Gaidano; Annarita Conconi; Richard Tsang; Mary K Gospodarowicz; Alessandro Rambaldi; Andrea Rossi; Elena Oldani; Massimo Federico; Stefano Luminari; Monica Bellei; Enrico M Pogliani; Fausto Rossini; Maria Elena Cabrera; Maurizio Martelli; Armando Lopez-Guillermo; Mario Busetto; Franco Cavalli; Emanuele Zucca; Sergio Cortelazzo
Journal:  Leuk Lymphoma       Date:  2011-02-21

Review 9.  Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge.

Authors:  E G Boerma; R Siebert; P M Kluin; M Baudis
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

10.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

View more
  1 in total

1.  Experimental study of doxorubicin interventional chemotherapy in the treatment of rabbit VX2 renal transplantation carcinoma.

Authors:  Shuyuan Zhao; Hui Yu; Nan Du
Journal:  Int J Clin Exp Med       Date:  2015-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.